目的:研究香苏通降散联合揿针疗法对IBS-D (脾胃虚弱证)的效果及血浆中血管活性肠肽(VIP)及P成分(SP)的改变,进一步探究其机制。方式:共纳入60例符合IBSD (腹泻型肠易激综合征)脾胃虚弱证入选标准的病人,随机数字表法分为香苏通降散联...目的:研究香苏通降散联合揿针疗法对IBS-D (脾胃虚弱证)的效果及血浆中血管活性肠肽(VIP)及P成分(SP)的改变,进一步探究其机制。方式:共纳入60例符合IBSD (腹泻型肠易激综合征)脾胃虚弱证入选标准的病人,随机数字表法分为香苏通降散联合揿针疗法(治疗组)和匹维溴铵片疗法组(对照组),每组各30例,以4周为1星期,在治愈前后检查两组病人主要症状评估、血浆VIP及SP水平,并作出效果评估。结论:(1) 治疗前两组之间的病症总分数对比,无统计学差异,存在一致性;治疗后两组间的病症总分数对比,临床治疗组小于对照组(P Objective: To study the effects of Xiangsu Tong Jiangsan combined with press needle therapy on IBS-D (spleen and stomach weakness syndrome) and the changes in plasma vascular active intestinal peptide (VIP) and P component (SP), further exploring its mechanism. Methods: A total of 60 patients meeting the criteria for IBS-D (Diarrhea Type Irritable Bowel Syndrome) with spleen and stomach weakness syndrome were included, randomly divided into Xiangsu Tong Jiangsan combined with press needle therapy (treatment group) and pivabromide tablets therapy group (control group), with 30 cases in each group, evaluated for main symptom assessment and plasma VIP and SP levels before and after 4 weeks of treatment, and assessed the effectiveness. Conclusion: (1) There was no statistically significant difference in the total symptom scores between the two groups before treatment, indicating consistency;after treatment, the total symptom scores of the clinical treatment group were significantly lower than those of the control group (P < 0.05), showing statistically significant differences. (2) After treatment, the VIP and SP levels of both groups of patients significantly increased. Over 4 weeks of observation, the differences between the two groups were highly significant, indicating that both the treatment group and the control group achieved good results. Overall, the conditions of both groups of patients significantly improved, with the treatment group performing better than the control group. Conclusion: Xiangsu Tong Jiangsan combined with press needle therapy can effectively treat diarrhea type irritable bowel syndrome (spleen and stomach weakness syndrome), significantly improving patient symptoms and serum VIP and SP levels, making it worthy of clinical promotion and application.展开更多
Objective:To investigate the molecular mechanism underlying the development of diarrhea-predominant irritable bowel syndrome (IBS-D) with spleen and kidney yang deficiency (SKYD) using a proteomics approach.Methods:Ma...Objective:To investigate the molecular mechanism underlying the development of diarrhea-predominant irritable bowel syndrome (IBS-D) with spleen and kidney yang deficiency (SKYD) using a proteomics approach.Methods:Male Sprague-Dawley rats (n =22) were divided into IBS-D (n =12) and normal control (n =10) groups.SKYD was then modeled in IBS-D rats by a combination of acetic acid enema,bondage,rectal dilation,tail stimulation,and Senna gavage.Colon tissue samples were subsequently collected and examined by Q Exactive mass spectrometry to identify differentially expressed proteins between the two groups.Results:The occurrence of SKYD/IBS-D was associated with ribosomal protein S23 (Rps23),protein phosphatase 2 catalytic subunit alpha (Pp2a),and growth factor receptor-bound protein 2 (Grb2),which are involved in the ribosome,neurotrophin signaling,and Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathways.Conclusion:These data suggest that SKYD/IBS-D pathophysiology likely involves inflammation,cell growth,apoptosis,stress granule formation,immune activation,loss of epithelial cell integrity,and visceral hypersensitivity.展开更多
文摘目的:研究香苏通降散联合揿针疗法对IBS-D (脾胃虚弱证)的效果及血浆中血管活性肠肽(VIP)及P成分(SP)的改变,进一步探究其机制。方式:共纳入60例符合IBSD (腹泻型肠易激综合征)脾胃虚弱证入选标准的病人,随机数字表法分为香苏通降散联合揿针疗法(治疗组)和匹维溴铵片疗法组(对照组),每组各30例,以4周为1星期,在治愈前后检查两组病人主要症状评估、血浆VIP及SP水平,并作出效果评估。结论:(1) 治疗前两组之间的病症总分数对比,无统计学差异,存在一致性;治疗后两组间的病症总分数对比,临床治疗组小于对照组(P Objective: To study the effects of Xiangsu Tong Jiangsan combined with press needle therapy on IBS-D (spleen and stomach weakness syndrome) and the changes in plasma vascular active intestinal peptide (VIP) and P component (SP), further exploring its mechanism. Methods: A total of 60 patients meeting the criteria for IBS-D (Diarrhea Type Irritable Bowel Syndrome) with spleen and stomach weakness syndrome were included, randomly divided into Xiangsu Tong Jiangsan combined with press needle therapy (treatment group) and pivabromide tablets therapy group (control group), with 30 cases in each group, evaluated for main symptom assessment and plasma VIP and SP levels before and after 4 weeks of treatment, and assessed the effectiveness. Conclusion: (1) There was no statistically significant difference in the total symptom scores between the two groups before treatment, indicating consistency;after treatment, the total symptom scores of the clinical treatment group were significantly lower than those of the control group (P < 0.05), showing statistically significant differences. (2) After treatment, the VIP and SP levels of both groups of patients significantly increased. Over 4 weeks of observation, the differences between the two groups were highly significant, indicating that both the treatment group and the control group achieved good results. Overall, the conditions of both groups of patients significantly improved, with the treatment group performing better than the control group. Conclusion: Xiangsu Tong Jiangsan combined with press needle therapy can effectively treat diarrhea type irritable bowel syndrome (spleen and stomach weakness syndrome), significantly improving patient symptoms and serum VIP and SP levels, making it worthy of clinical promotion and application.
基金grants from the National Natural Science Foundation of China(no.81403389)the Beijing Key Laboratory of Functional Gastrointestinal Disorders Diagnosis and Treatment of Traditional Chinese Medicine(no.BZ0374).
文摘Objective:To investigate the molecular mechanism underlying the development of diarrhea-predominant irritable bowel syndrome (IBS-D) with spleen and kidney yang deficiency (SKYD) using a proteomics approach.Methods:Male Sprague-Dawley rats (n =22) were divided into IBS-D (n =12) and normal control (n =10) groups.SKYD was then modeled in IBS-D rats by a combination of acetic acid enema,bondage,rectal dilation,tail stimulation,and Senna gavage.Colon tissue samples were subsequently collected and examined by Q Exactive mass spectrometry to identify differentially expressed proteins between the two groups.Results:The occurrence of SKYD/IBS-D was associated with ribosomal protein S23 (Rps23),protein phosphatase 2 catalytic subunit alpha (Pp2a),and growth factor receptor-bound protein 2 (Grb2),which are involved in the ribosome,neurotrophin signaling,and Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathways.Conclusion:These data suggest that SKYD/IBS-D pathophysiology likely involves inflammation,cell growth,apoptosis,stress granule formation,immune activation,loss of epithelial cell integrity,and visceral hypersensitivity.
